NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Upstream Bio, Inc. (UPB) Stock Analysis

Upstream Bio, Inc. (UPB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

UPB

$2.80

−$0.02 (−0.71%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare UPB with… →

UPB Key Statistics

As of Oct 21, 2026
Trading
Open
$2.83
Previous Close
$2.82
Day's Range
2.77–2.98
52-Week Range
2.74–33.68
Volume
1.41M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.39
Valuation
Market Cap
$153.36M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
48.56
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.88
Financials (FY)
Revenue (FY)
$2.85M+20.42%
Net Income (FY)
−$143.44M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
54.77M
1-Year Return
−87.46%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
772.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, UPB closed at $2.80, −87.46% over 1 year.

Upstream Bio, Inc. (UPB) has a market capitalization of $153.36M.

In fiscal 2025, UPB reported revenue of $2.85M.

UPB Stock Return by Calendar Year

Upstream Bio, Inc. (UPB) return since Oct 2024: what $10,000 became

1 year
$10,000 $1,254
−87.46%
Since Oct 2024
$10,000 $1,273
−87.27%

If you had invested $10,000 in Upstream Bio, Inc. (UPB) at the close on October 11, 2024, the earliest close on record here, it would have been worth $1,273 at the close on October 21, 2026: −87.27% in total, −63.85% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−89.69%
2025+65.15%
2024 (partial year)−25.27%

As of October 21, 2026.

UPB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.85M−$143.44M−5,026.0%
2024$2.37M−$62.81M−2,650.0%
2023$2.38M−$20.54M−862.9%
2022$1.21M−$23.87M−1,969.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.85M—−$160.36M−$143.44M−5,026.0%
2024$2.37M—−$77.76M−$62.81M−2,650.0%
2023$2.38M—−$40.11M−$20.54M−862.9%
2022$1.21M—−$23.91M−$23.87M−1,969.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

UPB Valuation vs Biotechnology Median

Median of 608 stocks
MetricUPBBiotechnology medianvs median
P/S ratio48.5613.303.7x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Upstream Bio, Inc. (UPB) at $153.36M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 75 employees.

The most recent close on file for UPB is $2.80, dated October 21, 2026. That is −$0.02 (−0.71%) against the previous close. Over the past 52 weeks the price has ranged from $2.74 to $33.68. The latest close sits 2.19% above that 52-week low.

Financial Health

In fiscal 2025, Upstream Bio, Inc. reported revenue of $2.85M. Against the prior fiscal year total of $2.37M, that is a change of +20.42%. The same year closed with a net loss of $143.44M. Earnings per share on a trailing basis come to −2.88.

Across the 4 fiscal years on file, revenue moves from $1.21M in 2022 to $2.85M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 48.56 times revenue. On price-to-sales that is 3.7 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −87.46%. The stored price history starts on October 11, 2024, and the total return since then is −87.27%. Beta against the wider market is reported at 1.39. Daily returns over the trailing 2 years annualize to a volatility of 88.8%.

Growth & Income

The record shows no dividend for UPB.

The record holds one complete calendar year, 2025, which returned +65.15%. 2026 is still running; the total return is −89.69% year to date.

Peer Comparison

Upstream Bio, Inc. (UPB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Upstream Bio, Inc. UPB $153.36M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Upstream Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Upstream Bio, Inc.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Visit website →